Knight Therapeutics Announces Launch of WYNZORA® in Canada

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Knight Therapeutics Announces Launch of WYNZORA® in CanadaAuthor of the article:Last updated 4 minutes ago MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. WYNZORA® is indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older.1THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an Account“The launch of WYNZORA® in Canada reflects our commitment to continuing to grow our Canadian platform and bring innovative treatment options to patients. WYNZORA®‘s unique aqueous cream formulation, enabled by PAD Technology™, offers patients and healthcare providers a clinically proven option that combines efficacy with ease of use, an important consideration for a chronic condition that requires long-term management.” said Samira Sakhia, President and Chief Executive Officer, Knight Therapeutics Inc.Knight obtained the Canadian rights to WYNZORA® through its June 2025 acquisition of the assets of Paladin Pharma Inc. (“Paladin”). Paladin had entered into a license agreement with MC2 Therapeutics Ltd. (“MC2”) to commercialize WYNZORA® in Canada in November 2024. MC2 is a private pharmaceutical company headquartered in Hørsholm, Denmark and in Guildford, United Kingdom. Knight announced Health Canada approval of WYNZORA® in December 2025.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againWYNZORA® is a cream-based fixed dose combination of CAL and BDP for topical treatment of psoriasis vulgaris developed by MC2. WYNZORA® has a broad mode of action by targeting keratinocyte proliferation and differentiation and inhibiting expression of pro-inflammatory hallmark cytokines such as IL-23, IL-17A/F and TNF-α. In WYNZORA®, the combination of CAL and BDP has greater anti-inflammatory and anti-proliferative effects than either component alone. WYNZORA® is uniquely enabled by MC2’s formulation and drug delivery system PAD TechnologyTM, allowing an effective convenient-to-use aqueous cream formulation. WYNZORA® Cream was first approved in the United States by the FDA in July 2020, followed by approvals in Europe in 2021, Australia in November 2024, and Canada in December 2025. WYNZORA® is a registered trademark of MC2. All other trademarks are the property of their respective owners.Psoriasis is a chronic, immune-mediated inflammatory disease of the skin.2 It is often characterized by the presence of erythematous plaques, usually covered with silver, flaking scales. These plaques may be itchy or painful; depending on their extent and location, they may also be physically debilitating or socially isolating.3,4 An estimated 1 million Canadians and 125 million people worldwide, are affected by psoriasis.4 Chronic plaque psoriasis (psoriasis vulgaris) is the most common type and accounts for 80% to 90% of cases.5 The severity of disease may vary among patients, ranging from mild to moderate to severe.5 The clinical course of psoriasis is unpredictable, with fluctuating severity over time.6Common symptoms of psoriasis include itching, redness, flaking and scaling. Itch is considered one of the most bothersome symptoms, with patients reporting itch reduction the most important treatment goal.7 Yet, the disease burden of psoriasis extends far beyond the physical dermatological symptoms. Psoriasis is considered a systemic inflammatory disorder, similar to rheumatoid arthritis, Crohn’s disease, and systemic lupus erythematosus.8This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.The Health Canada approval was based on the results of two randomized, investigator-blind, vehicle-controlled 8-week phase 3 trials (MC2-01-C2 and MC2-01-C7) in adults, with CAL/BDP gel/suspension included as an active comparator.9,10 The trials were designed to show superiority of WYNZORA® to vehicle and non-inferiority to CAL/BDP (50 mcg/g CAL and 0.5 mg/g BDP) gel/suspension.9,10Results from both trials demonstrated that WYNZORA® had superior efficacy compared to vehicle (p < 0.0001) for all confirmatory efficacy endpoints, including Physician Global Assessment (PGA) treatment success and mean percentage change from baseline in modified Psoriasis Area and Severity Index (mPASI) at Week 8 In addition, WYNZORA® was non-inferior to CAL/BDP gel/suspension at Week 8 for both PGA treatment success and mPASI.1,9,10The most frequently reported adverse reactions were application site reactions including irritation, pain, pruritus, eczema, exfoliation, telangiectasia and folliculitis, all occurring at a frequency below 1%.1MC2 Therapeutics is a private dermatology innovation company developing science-based topical solutions, from prescription therapies to advanced dermo-cosmetics, leveraging its proprietary PAD Technology® platform. Wynzora® Cream, MC2’s first PAD Technology®-based commercial product, was launched in the United States in 2020 and is now approved in multiple regions, including Europe, Australia and Canada, through partnerships with leading pharmaceutical companies specializing in dermatology. MC2 Therapeutics is headquartered in Hørsholm, Denmark, with additional R&D and development operations in Guildford, United Kingdom.About Knight Therapeutics Inc.Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.Forward-Looking Statements for KnightThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.Knight Therapeutics, Inc. Wynzora® (calcipotriol and betamethasone dipropionate cream) [product monograph]. Montreal, QC: Knight Therapeutics, Inc.; November 21, 2025.Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339Papp, K., Gulliver, W., Lynde, C., Poulin, Y., Ashkenas, J., & Canadian Psoriasis Guidelines Committee (2011). Canadian guidelines for the management of plaque psoriasis: overview. Journal of cutaneous medicine and surgery, 15(4), 210–219. https://doi.org/10.2310/7750.2011.10066Canadian Dermatology Association. Psoriasis. Accessed May 26, 2026. https://dermatology.ca/public-patients/diseases-conditions/skin-conditions/psoriasis/Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.Blackstone B, Patel R, Bewley A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis (Auckl). 2022;12:25-33. Published 2022 Mar 25. doi:10.2147/PTT.S328447.Lebwohl M, Langley RG, Paul C, et al. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatol Ther (Heidelb). 2022;12(1):61-78. doi:10.1007/s13555-021-00635-4.Lebwohl M. Psoriasis. Ann Intern Med. 2018;168(7):ITC49-ITC64. doi:10.7326/AITC201804030.Pinter A, Reich A, Arenberger P, et al. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37(11):2327-2335. doi:10.1111/jdv.19330Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream. J Drugs Dermatol. 2021;20(4):420-425. doi:10.36849/JDD.2021.5653CONTACT INFORMATION FOR KNIGHT:Investor Contact: Knight Therapeutics Inc. Samira SakhiaArvind UtchanahPresident & Chief Executive OfficerChief Financial OfficerT: 514.484.4483T: 514.484.4483Email: IR@knighttx.comEmail: IR@knighttx.comWebsite: www.knighttx.comWebsite: www.knighttx.comNotice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.